BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 30961661)

  • 1. GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner.
    Lin F; Xie YJ; Zhang XK; Huang TJ; Xu HF; Mei Y; Liang H; Hu H; Lin ST; Luo FF; Lang YH; Peng LX; Qian CN; Huang BJ
    J Exp Clin Cancer Res; 2019 Apr; 38(1):152. PubMed ID: 30961661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing GTSE-1 expression inhibits proliferation and invasion of hepatocellular carcinoma cells.
    Guo L; Zhang S; Zhang B; Chen W; Li X; Zhang W; Zhou C; Zhang J; Ren N; Ye Q
    Cell Biol Toxicol; 2016 Aug; 32(4):263-74. PubMed ID: 27240802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CK2-mediated CCDC106 phosphorylation is required for p53 degradation in cancer progression.
    Ning Y; Wang C; Liu X; Du Y; Liu S; Liu K; Zhou J; Zhou C
    J Exp Clin Cancer Res; 2019 Mar; 38(1):131. PubMed ID: 30885251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of G2 and S phase-expressed-1 contributes to cell proliferation, migration, and invasion via regulating p53/FoxM1/CCNB1 pathway and predicts poor prognosis in bladder cancer.
    Liu A; Zeng S; Lu X; Xiong Q; Xue Y; Tong L; Xu W; Sun Y; Zhang Z; Xu C
    Int J Biol Macromol; 2019 Feb; 123():322-334. PubMed ID: 30414902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
    Xiong J; Yang Q; Li J; Zhou S
    Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-promoting properties of miR-8084 in breast cancer through enhancing proliferation, suppressing apoptosis and inducing epithelial-mesenchymal transition.
    Gao Y; Ma H; Gao C; Lv Y; Chen X; Xu R; Sun M; Liu X; Lu X; Pei X; Li P
    J Transl Med; 2018 Feb; 16(1):38. PubMed ID: 29471858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRIM59 overexpression correlates with poor prognosis and contributes to breast cancer progression through AKT signaling pathway.
    Liu Y; Dong Y; Zhao L; Su L; Diao K; Mi X
    Mol Carcinog; 2018 Dec; 57(12):1792-1802. PubMed ID: 30175868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GTSE1 promotes cell migration and invasion by regulating EMT in hepatocellular carcinoma and is associated with poor prognosis.
    Wu X; Wang H; Lian Y; Chen L; Gu L; Wang J; Huang Y; Deng M; Gao Z; Huang Y
    Sci Rep; 2017 Jul; 7(1):5129. PubMed ID: 28698581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High G2 and S-phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis.
    Xu T; Ma M; Chi Z; Si L; Sheng X; Cui C; Dai J; Yu S; Yan J; Yu H; Wu X; Tang H; Yu J; Kong Y; Guo J
    Cancer Sci; 2018 Jun; 109(6):1787-1798. PubMed ID: 29660787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long Non-Coding RNA (LncRNA) HOXA11-AS Promotes Breast Cancer Invasion and Metastasis by Regulating Epithelial-Mesenchymal Transition.
    Li W; Jia G; Qu Y; Du Q; Liu B; Liu B
    Med Sci Monit; 2017 Jul; 23():3393-3403. PubMed ID: 28701685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer.
    Raza U; Saatci Ö; Uhlmann S; Ansari SA; Eyüpoğlu E; Yurdusev E; Mutlu M; Ersan PG; Altundağ MK; Zhang JD; Doğan HT; Güler G; Şahin Ö
    Oncotarget; 2016 Aug; 7(31):49859-49877. PubMed ID: 27409664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulated WDR26 serves as a scaffold to coordinate PI3K/ AKT pathway-driven breast cancer cell growth, migration, and invasion.
    Ye Y; Tang X; Sun Z; Chen S
    Oncotarget; 2016 Apr; 7(14):17854-69. PubMed ID: 26895380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA-binding protein RNPC1: acting as a tumor suppressor in breast cancer.
    Xue JQ; Xia TS; Liang XQ; Zhou W; Cheng L; Shi L; Wang Y; Ding Q
    BMC Cancer; 2014 May; 14():322. PubMed ID: 24884756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPOCK1/SIX1axis promotes breast cancer progression by activating AKT/mTOR signaling.
    Xu M; Zhang X; Zhang S; Piao J; Yang Y; Wang X; Lin Z
    Aging (Albany NY); 2020 Dec; 13(1):1032-1050. PubMed ID: 33293473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity.
    Qin T; Li B; Feng X; Fan S; Liu L; Liu D; Mao J; Lu Y; Yang J; Yu X; Zhang Q; Zhang J; Song B; Li M; Li L
    J Exp Clin Cancer Res; 2018 Nov; 37(1):287. PubMed ID: 30482232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abrogation of p53 function leads to metastatic transcriptome networks that typify tumor progression in human breast cancer xenografts.
    D'Assoro AB; Leontovich A; Amato A; Ayers-Ringler JR; Quatraro C; Hafner K; Jenkins RB; Libra M; Ingle J; Stivala F; Galanis E; Salisbury JL
    Int J Oncol; 2010 Nov; 37(5):1167-76. PubMed ID: 20878064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin αvβ3 and activating FAK/PI3K/AKT signaling.
    Luo J; Yao JF; Deng XF; Zheng XD; Jia M; Wang YQ; Huang Y; Zhu JH
    J Exp Clin Cancer Res; 2018 Feb; 37(1):23. PubMed ID: 29426357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting TPX2 suppresses proliferation and promotes apoptosis via repression of the PI3k/AKT/P21 signaling pathway and activation of p53 pathway in breast cancer.
    Chen M; Zhang H; Zhang G; Zhong A; Ma Q; Kai J; Tong Y; Xie S; Wang Y; Zheng H; Guo L; Lu R
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):74-82. PubMed ID: 30454896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiated pre-adipocytes promote proliferation, migration and epithelial-mesenchymal transition in breast cancer cells of different p53 status.
    Avşar Abdik E
    Mol Biol Rep; 2021 Jun; 48(6):5187-5198. PubMed ID: 34213707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IMPDH2 promotes colorectal cancer progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways.
    Duan S; Huang W; Liu X; Liu X; Chen N; Xu Q; Hu Y; Song W; Zhou J
    J Exp Clin Cancer Res; 2018 Dec; 37(1):304. PubMed ID: 30518405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.